1. Show article details.

    NovaBay Pharmaceuticals Expands Avenova® Consumer Marketing through Affiliate Programs and Enhanced Lifestyle Public Relations

    Business Wire – 6:50 AM ET 09/24/2020

    NovaBay® Pharmaceuticals, Inc. announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobial lid and lash spray and promote online sales. NovaBay has engaged PartnerCentric, Inc. for affiliate marketing programs and HVM Communications for enhanced public relations featuring consumer-oriented, lifestyle messaging.

  2. Show article details.

    BRIEF-Novabay Pharmaceuticals Entered First Amendment To That Certain Services Agreement With TLF Bio Innovation Lab

    Reuters – 9:40 AM ET 09/10/2020

    NovaBay Pharmaceuticals Inc (NBY): * NovaBay Pharmaceuticals Inc (NBY) - ENTERED FIRST AMENDMENT TO THAT CERTAIN SERVICES AGREEMENT WITH TLF BIO INNOVATION LAB. * NovaBay Pharmaceuticals Inc (NBY) - AGREED TO AMEND CERTAIN PROVISIONS OF AGREEMENT PRIMARILY RELATED TO EQUITY AWARDS, AND RELATED MILESTONES.

  3. Show article details.

    NovaBay Announces that Avenova is Now Available with “Subscribe & Save”

    Business Wire – 6:50 AM ET 09/08/2020

    Repays Secured Convertible Promissory Note NovaBay® Pharmaceuticals, Inc. announces the availability of “subscribe & save” for repeat orders of Avenova® antimicrobial lid & lash solution on Avenova.com and Amazon.com. “Our upgraded online product listings will allow customers to automate recurring orders, thereby increasing our recurring revenue and improving visibility on future sales,” said J...

  4. Show article details.

    BRIEF-NovaBay Appoints CEO Justin Hall To Its Board Of Directors

    Reuters – 7:52 AM ET 08/24/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY APPOINTS CEO JUSTIN HALL TO ITS BOARD OF DIRECTORS. * NovaBay Pharmaceuticals Inc (NBY) - BOARD MEMBERSHIP REMAINS AT SIX Source text for Eikon: Further company coverage:

  5. Show article details.

    BRIEF-Novabay Pharmaceuticals Files Prospectus For Resale Of 6.9 Mln Warrant Shares

    Reuters – 4:44 PM ET 08/21/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS-FILES PROSPECTUS FOR RESALE OF 6.9 MILLION WARRANT SHARES TO BE ISSUED UPON EXERCISE OF WARRANTS ISSUED TO SELLING SECURITYHOLDERS Source text: Further company coverage:

  6. Show article details.

    BRIEF-NovaBay Pharmaceuticals Expands Avenova's Online Distribution

    Reuters – 7:44 AM ET 08/18/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY EXPANDS AVENOVA’S ONLINE DISTRIBUTION. * NovaBay Pharmaceuticals Inc (NBY) - LAUNCH OF AVENOVA ON WALMART.COM Source text for Eikon: Further company coverage:

  7. Show article details.

    NovaBay Expands Avenova’s Online Distribution

    Business Wire – 6:50 AM ET 08/18/2020

    Walmart.com joins Amazon.com and Avenova.com in offering Avenova, the only facial spray confirmed through independent laboratory testing to kill the SARS-CoV-2 virus NovaBay® Pharmaceuticals, Inc. announces the launch of Avenova® on Walmart.com, increasing the availability of its unique facial sanitizer confirmed through independent laboratory testing to kill the SARS-CoV-2 virus on hard surfa...

  8. Show article details.

    BRIEF-Novabay Pharmaceuticals Reports Second Quarter 2020 Financial Results

    Reuters – 5:23 PM ET 08/06/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS. * Q2 LOSS PER SHARE $0.15. * CONFIDENT WILL RETAIN NYSE CONTINUED-LISTING COMPLIANCE FOLLOWING OUR SUCCESSFUL ATM FINANCING. * EXPECT FINANCIAL RESOURCES TO BE SUFFICIENT TO FUND CURRENT OPERATIONS THROUGH 2021. * NET LOSS FOR Q2 WAS $0.15 PER SHARE Source text for Eikon: Further company coverage:

  9. Show article details.

    NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results

    Business Wire – 4:05 PM ET 08/06/2020

    Product revenue increased 122% to $4.0 million driven by sales of KN95 masks; operating loss narrowed 21% Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. reports financial results for the three and six months ended June 30, 2020 and provides a business update.

  10. Show article details.

    NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6

    Business Wire – 6:50 AM ET 07/27/2020

    NovaBay® Pharmaceuticals, Inc. announces it will report financial results for the three and six months ended June 30, 2020 after market close on Thursday, August 6, 2020 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.

  11. Show article details.

    BRIEF-Novabay Says Anticipates Reporting Q2 Net Sales Increased By About 100% And Operating Loss Declined By About 25% From Prior Quarter

    Reuters – 9:27 AM ET 07/21/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY - ANTICIPATES REPORTING Q2 NET SALES INCREASED BY ABOUT 100% AND OPERATING LOSS DECLINED BY ABOUT 25% FROM PRIOR QUARTER Source text: [ID:https://bit.ly/3hnwZdS] Further company coverage:

  12. Show article details.

    BRIEF-Novabay Says Laboratory Results Confirm Avenova Kills Sars-Cov-2 (Covid-19 Virus)

    Reuters – 8:13 AM ET 07/13/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS ANNOUNCES LABORATORY RESULTS CONFIRM AVENOVA KILLS SARS-COV-2. * NovaBay Pharmaceuticals Inc (NBY) - TEST RESULTS WILL BE SUBMITTED TO EPA FOR EPA'S APPROVED LIST OF DISINFECTANTS FOR USE AGAINST SARS-COV-2.

  13. Show article details.

    NovaBay Pharmaceuticals Announces Laboratory Results Confirm Avenova Kills SARS-CoV-2 (COVID-19 Virus)

    Business Wire – 6:50 AM ET 07/13/2020

    NovaBay® Pharmaceuticals, Inc. announces testing results from an independent third-party laboratory confirming that Avenova®, NovaBay’s proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2. “Since Avenova’s inception, we have known it to be a powerful antimicrobial spray solution, effective against all types of pathogens, including a wide variety of viruses, bacteria, and fungi.

Page:

Today's and Upcoming Events

  • Nov
    05

    NBY to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    06

    NBY announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.